Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 25 April 2022 post announcement of financial results of the Company for the quarter and year ended 31 March 2022. The above information will also be hosted on Company's website of at www.tatvachintan.com. This is for your information and records.
28-04-2022
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find enclosed herewith copies of newspaper advertisement pertaining to extract of financial results of the Company for the quarter and year ended 31 march 2022, published in Financial Express (English edition) and Vadodara Samachar (Gujarati edition) on 26 April 2022. The above information will also be hosted on Company's website of at www.tatvachintan.com. Kindly take the same on record and disseminate to the public at large.
26-04-2022
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Earnings Call Recording

 Pursuant to Regulation 46(2)(oa) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform the exchanges that the recording of the Earnings Call held on Monday, 25 April 2022 at 5:00 pm IST is available on the website of the Company. The recording can be accessed from the following link: https://www.tatvachintan.com/wp-content/uploads/2022/04/Audio-Link.mp3
25-04-2022
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter and year ended 31 March 2022. The above information is also being made available on the website of the Company at www.tatvachintan.com. This is for your information and records.
25-04-2022

Earnings Call for Q4FY22 of Tatva Chintan Pharma Chem

 Conference Call with Tatva Chintan Pharma Chem Management and Analysts on Q4FY22 Performance and Outlook. Listen to the full earnings transcript.
25-04-2022
Bigul

Q4FY22 Quarterly Result Announced for Tatva Chintan Pharma Chem Ltd.

 Tatva Chintan Pharma Chem's profit falls 17% YoY in Q4FY22, revenue down 9% Tatva Chintan Pharma Chem announced Q4FY22 results: FY22: Revenue from Operations for the year FY22 was Rs 4,336 million higher by 44% vs FY21 EBITDA was Rs 1,171 million higher by 64% EBIDTA Margin for the year was at 27% vs 24% in FY21 Net Profit was Rs 959 million higher by 83% Net Profit Margin for the year was at 22% vs 17% in FY21 Basic and Diluted EPS was Rs 44.59 per share vs Rs 26.02 in FY21 Q4FY22 (YoY): Revenue from Operations for the quarter was Rs 985 million, declined by 9% EBITDA for the quarter was Rs 223 million, declined by 18% EBIDTA Margin for the quarter was at 23% vs 25% in Q4FY21 Net Profit for the quarter was Rs 175 million declined by 17% Net Profit Margin for the quarter was at 18% vs 19% in Q4FY21 Basic and Diluted EPS for the quarter was Rs 7.9 per share vs Rs 10.5 in Q4FY21 Commenting on the year FY22 Mr. Chintan Shah, Managing Director, said, "FY22 has been a special year, as for the first time, we crossed the revenue mark of Rs 4,000 million, we crossed an PBT of more than Rs 1,000 million, our exports revenue crossed the mark of Rs 3,000 million for the first time and in fact our export revenue of FY22 has exceeded the total revenue of FY21. Last and most memorable was successfully getting listed on Indian Stock Exchange. We are pleased to inform you that on 'together for sustainability' platform, we have drastically improved our Audit score from 54% to 87%. This is a matter of pride for TATVA CHINTAN and it also demonstrates our genuine efforts in moving towards sustainable solutions. Our approach of being an integrated manufacturer, producing niche specialty chemical, having leadership position across product categories, diversified geographically with 79% exports as on FY22, focus on green chemistry by using cutting edge technology, in-house R&D; facility with 24 employees including 10 senior highly qualified scientists has helped us steadily grow our presence and more importantly helped grow the customer’s confidence in TATVA CHINTAN, despite the turbulent macroeconomic situation of covid lockdowns and geopolitical tensions globally. We got listed on NSE/BSE on 29 July 2021, out of our net IPO proceeds of Rs 2,072.81 million, Rs 129.59 million have been utilized during Q4FY22 taking the total amount utilized to Rs 640.97 million as on 31 March 2022. The expansion is underway at our Dahej SEZ manufacturing plant and at our R&D; facility at Vadodara." Result PDF
25-04-2022
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Press Release on financial results of the Company for the quarter and year ended 31 March 2022. The above information is also being made available on the website of the Company at www.tatvachintan.com. This is for your information and records.
25-04-2022
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Corporate Action-Board approves Dividend

 The Board Recommended a Final Dividend of Rs. 2/- (20%) per equity share of Rs. 10/- each fully paid (subject to deduction of tax, if any) on the equity share capital of Rs. 22,16,50,620/- (2,21,65,062 equity shares of Rs. 10/- each) for the financial year 2021-22. This shall be paid subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.
25-04-2022
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Year Ended On 31 March 2022

 Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended on 31 March 2022
25-04-2022
Bigul

Tatva Chintan Pharma Chem Ltd - 543321 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 25.04.2022

 Outcome Of The Board Meeting Held On 25.04.2022
25-04-2022
Next Page
Close

Let's Open Free Demat Account